Alkermes plc (ALKS)

Market Cap	4.60B
Revenue (ttm)	1.51B
Net Income (ttm)	348.45M
Shares Out	165.08M
EPS (ttm)	2.08
PE Ratio	13.41
Forward PE	20.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,244,748
Open	27.52
Previous Close	27.39
Day's Range	27.38 - 28.28
52-Week Range	25.17 - 36.45
Beta	0.49
Analysts	Strong Buy
Price Target	41.29 (+48.15%)
Earnings Date	Oct 23, 2025

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS
• Website: https://www.alkermes.com

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Analyst Summary

According to 14 analysts, the average rating for ALKS stock is "Strong Buy." The 12-month stock price target is $41.29, which is an increase of 48.15% from the latest price.

Price Target

$41.29

(48.15% upside)

Analyst Consensus: Strong Buy